预约演示
更新于：2025-06-05
188Re-HEDP
铼[Re-188]依替膦酸盐
更新于：2025-06-05
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段无进展临床3期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C2H8O7P2Re |
InChIKeyIRNIPRCGJQWCNJ-NLQOEHMXSA-N |
CAS号145571-93-3 |
使用我们的ADC技术数据为新药研发加速。
登录
或
关联
10
项与 铼[Re-188]依替膦酸盐 相关的临床试验CTR20200377
评价铼[188Re]依替膦酸盐注射液在去势抵抗性前列腺癌骨转移患者中的药代动力学和药效学临床研究
CTR20181152
多中心、随机、双盲、安慰剂平行对照评价[188Re]依替膦酸盐注射液对CRPC癌骨转移患者的耐受性、有效性和安全性
NCT03458559
Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study
100 项与 铼[Re-188]依替膦酸盐 相关的临床结果
登录后查看更多信息
100 项与 铼[Re-188]依替膦酸盐 相关的转化医学
登录后查看更多信息
100 项与 铼[Re-188]依替膦酸盐 相关的专利（医药）
登录后查看更多信息
53
项与 铼[Re-188]依替膦酸盐 相关的文献（医药）2021-07-01International journal of clinical oncology3区 · 医学
Efficacy and safety of 188Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study
3区 · 医学
Article
作者: Liu, Zengli ; Li, Jun ; Chen, Ping ; Wu, Yiwei ; Kuai, Dayu ; Zhang, Guangming ; Liu, Xingdang ; Wang, Yuankai ; Gui, Jicong ; ZhangLi, Yingjian Biao ; Lv, Zhongwei ; Zuo, Changjing ; Liu, Congjin
PURPOSE:
To investigate the pain-relieving effect and safety of three different doses of 188Re-hydroxyethylidine diphosphonate (HEDP) in patients with lung cancer and bone metastases.
METHODS:
For this randomised, phase 2 and multicenter trial, we enrolled patients with lung carcinoma and multifocal bone metastases and excluded patients who had received bisphosphonates or external-beam radiotherapy within the previous 4 weeks. Fifty-four patients were randomized to receive a single injection of 188Re-HEDP, at doses of 30, 40 or 50 MBq/kg (interval, 12 weeks). Patients were followed-up by assessment of numerical rating scale (NRS) score, global quality of life (QOL) score and adverse events (AEs). ANOVA analysis, Chi-Squared test and LSD-t test were used in this study.
RESULTS:
Significantly decreased NRS scores relative to baseline were observed in 40 MBq/kg group (Week 0 vs. Week 12: 6.0 ± 1.4 vs. 4.8 ± 2.5, P = 0.033) and 50 MBq/kg group (Week 0 vs. Week 12: 5.5 ± 1.5 vs. 4.5 ± 2.9, P = 0.046). Significant change of global QOL score from baseline was observed in 40 MBq/kg group at week 8 (global QOL score: P = 0.024, pain score: P = 0.041) and 50 MBq/kg group (pain score: P = 0.021) at week 12. No patients withdrew trial because of AEs in three groups.
CONCLUSIONS:
188Re-HEDP at dose of 40 and 50 MBq/kg was generally effective to alleviate pain and improve QOL in lung cancer patients with painful bone metastases. 188Re-HEDP was safe and well-tolerated.
2019-11-01JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Appraisement of 186/188Re-HEDP, a new compositional radiopharmaceutical
作者: Ranjbar, Hassan ; Pourhabib, Zahra ; Bahrami Samani, Ali ; Shokri, Ali Asghar
Undoubtedly radionuclide therapy is the next phase of nuclear medicine development. 188Re-HEDP and 186Re-HEDP are therapeutic radiopharmaceuticals which have been used to treat bone metastases.With regard to their complementary features, in this study, as new idea their combined effects have been investigated with preparing the cocktail of 188/186Re-HEDP with radiochem. purity nearly 99%.The 188/186Re-HEDP biodistribution was checked in rats' tissues up to 72 h.The produced 188/186Re-HEDP properties suggest a new bone palliative radiopharmaceutical to overcome bone metastases.
2019-01-01JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Comparison of the efficacy of 177Lu-EDTMP, 177Lu-DOTMP and 188Re-HEDP towards bone osteosarcoma: an in vitro study
作者: Dash, Ashutosh ; Das, Tapas ; Vats, Kusum ; Kumar, Chandan ; Sharma, Rohit ; Sarma, H. D. ; Mallia, Madhav B.
Among the radiopharmaceuticals harnessed for palliation of bone pain in osseous metastases patients, 177Lu labeled phosphonates such as EDTMP (Ethylene diamine tetramethylene phosphonic acid) as well as DOTMP (1,4,7,10-tetraaza-cyclo-dodecane-1,4,7,10 tetraethylene phosphonic acid) and 188Re-labeled HEDP (1,1-hydroxyethylene diphosphonic acid) seem to be the most favorable for treatment of small and medium/large size bone lesions, resp.A comparative assessment of 177Lu-EDTMP, 177Lu-DOTMP and 188Re-HEDP in osteosarcoma tumor cell line was carried out to evaluate their relative efficacy.It was found that 188Re-HEDP is more potent in induction of cell toxicity and apoptosis compared to the 177Lu-EDTMP and 177Lu-DOTMP, thus 188Re-HEDP might have great clin. significance.
1
项与 铼[Re-188]依替膦酸盐 相关的新闻（医药）2024-07-07
·药事纵横
并购放射疗法财报
100 项与 铼[Re-188]依替膦酸盐 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期前列腺癌 | 临床3期 | 荷兰 | 2018-05-16 | |
| 转移性去势抵抗性前列腺癌 | 临床3期 | 荷兰 | 2018-05-16 | |
| 前列腺腺癌 | 临床2期 | 中国 | 2018-10-24 | |
| 前列腺腺癌 | 临床2期 | 中国 | 2018-10-24 | |
| 去势抵抗性前列腺癌 | 临床2期 | 中国 | 2018-10-24 | |
| 去势抵抗性前列腺癌 | 临床2期 | 中国 | 2018-10-24 | |
| 骨转移癌 | 临床2期 | 中国 | 2013-09-12 | |
| 骨转移癌 | 临床2期 | 中国 | 2013-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 12 | 製選襯壓構願範襯繭艱(鑰顧餘獵艱糧製鹹鹽鹹) = after the 2nd cycle of re-188 (thrombopenia grade 3 causing delay of the next cycle of treatment) 餘齋鏇夢積遞餘鹽窪觸 (憲餘簾醖糧鹹衊衊獵鏇 ) | - | 2016-05-20 | |||
N/A | 21 | 衊鬱鹽衊遞網鏇窪壓遞(廠蓋襯鹽壓範鹽衊鏇醖) = Relevant but reversible hematotoxicity (grade 3/4) occurred in 6 patients (28.5%) and 8 administrations (11.9%) with leukopenia and thrombocytopenia in 3% and anemia in 7.5% 構鏇艱醖壓繭製衊顧鏇 (顧鹽繭襯積膚窪艱衊選 ) | 积极 | 2014-11-05 | |||
N/A | 61 | 觸窪壓鏇築願鏇蓋廠衊(鏇鹽遞構鏇襯鑰鏇鬱艱) = 齋遞廠廠鹹築艱構襯選 淵齋壓壓鑰膚製夢觸觸 (蓋願範廠襯廠餘築齋窪 ) | 积极 | 2004-07-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用